SG11202102865WA - Pharmaceutical combination for the treatment of cancer - Google Patents
Pharmaceutical combination for the treatment of cancerInfo
- Publication number
- SG11202102865WA SG11202102865WA SG11202102865WA SG11202102865WA SG11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- pharmaceutical combination
- pharmaceutical
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737155P | 2018-09-27 | 2018-09-27 | |
| PCT/US2019/053651 WO2020069439A1 (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102865WA true SG11202102865WA (en) | 2021-04-29 |
Family
ID=69953118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102865WA SG11202102865WA (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395351A1 (en) |
| EP (1) | EP3856784A4 (en) |
| JP (1) | JP7451506B2 (en) |
| KR (1) | KR20210065146A (en) |
| CN (1) | CN113454114A (en) |
| AU (1) | AU2019351267A1 (en) |
| BR (1) | BR112021005525A2 (en) |
| CA (1) | CA3114173A1 (en) |
| IL (1) | IL281782A (en) |
| MX (1) | MX2021003274A (en) |
| SG (1) | SG11202102865WA (en) |
| WO (1) | WO2020069439A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2285989B1 (en) | 2008-05-15 | 2016-11-16 | The University of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| US9759725B2 (en) * | 2012-08-02 | 2017-09-12 | Fred Hutchinson Cancer Research Center | Treatment-induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins |
| US20160376373A1 (en) * | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AU2017208819B2 (en) * | 2016-01-22 | 2023-10-19 | MabQuest SA | PD1 specific antibodies |
| AU2018221557C1 (en) | 2017-02-14 | 2021-10-14 | Novartis Ag | Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination |
-
2019
- 2019-09-27 AU AU2019351267A patent/AU2019351267A1/en active Pending
- 2019-09-27 SG SG11202102865WA patent/SG11202102865WA/en unknown
- 2019-09-27 EP EP19866195.1A patent/EP3856784A4/en active Pending
- 2019-09-27 CN CN201980076608.3A patent/CN113454114A/en active Pending
- 2019-09-27 MX MX2021003274A patent/MX2021003274A/en unknown
- 2019-09-27 CA CA3114173A patent/CA3114173A1/en active Pending
- 2019-09-27 JP JP2021517299A patent/JP7451506B2/en active Active
- 2019-09-27 WO PCT/US2019/053651 patent/WO2020069439A1/en unknown
- 2019-09-27 BR BR112021005525-8A patent/BR112021005525A2/en unknown
- 2019-09-27 US US17/279,857 patent/US20210395351A1/en active Pending
- 2019-09-27 KR KR1020217012004A patent/KR20210065146A/en unknown
-
2021
- 2021-03-24 IL IL281782A patent/IL281782A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210065146A (en) | 2021-06-03 |
| JP2022502434A (en) | 2022-01-11 |
| AU2019351267A1 (en) | 2021-05-13 |
| BR112021005525A2 (en) | 2021-06-29 |
| JP7451506B2 (en) | 2024-03-18 |
| EP3856784A1 (en) | 2021-08-04 |
| EP3856784A4 (en) | 2022-10-19 |
| WO2020069439A1 (en) | 2020-04-02 |
| US20210395351A1 (en) | 2021-12-23 |
| CA3114173A1 (en) | 2020-04-02 |
| IL281782A (en) | 2021-05-31 |
| CN113454114A (en) | 2021-09-28 |
| MX2021003274A (en) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054316T2 (en) | Pharmaceutical composition for cancer treatment | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
| IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| IL275525A (en) | Pharmaceutical composition for the treatment of cancer | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| EP3897602A4 (en) | Pharmaceutical combinations for the treatment of cancer | |
| ZA201907286B (en) | A pharmaceutical combination for the treatment of a cancer | |
| IL273835A (en) | Combination product for the treatment of cancer | |
| PL3630754T3 (en) | Isoindoline-acetylene compounds for the treatment of cancer | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer | |
| IL281782A (en) | Pharmaceutical combination for the treatment of cancer | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| GB201719584D0 (en) | Pharmaceutical compositions for the treatment of cancer |